153 related articles for article (PubMed ID: 9669149)
21. [Male osteoporosis: current treatments and future options].
Romagnoli E; Paglia F; Dionisi S; De Geronimo S; Pepe J; Di Virgilio R; Minisola S
Clin Ter; 2003; 154(1):49-53. PubMed ID: 12854284
[TBL] [Abstract][Full Text] [Related]
22. Parathyroid hormone: an anabolic treatment for osteoporosis.
Morley P; Whitfield JF; Willick GE
Curr Pharm Des; 2001 May; 7(8):671-87. PubMed ID: 11375775
[TBL] [Abstract][Full Text] [Related]
23. Investigational anabolic therapies for osteoporosis.
Trivedi R; Goswami R; Chattopadhyay N
Expert Opin Investig Drugs; 2010 Aug; 19(8):995-1005. PubMed ID: 20629616
[TBL] [Abstract][Full Text] [Related]
24. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.
Brixen KT; Christensen PM; Ejersted C; Langdahl BL
Basic Clin Pharmacol Toxicol; 2004 Jun; 94(6):260-70. PubMed ID: 15228497
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms of anabolic therapies for osteoporosis.
Canalis E; Giustina A; Bilezikian JP
N Engl J Med; 2007 Aug; 357(9):905-16. PubMed ID: 17761594
[No Abstract] [Full Text] [Related]
26. Treatment of osteoporosis with parathyroid hormone and teriparatide.
Pleiner-Duxneuner J; Zwettler E; Paschalis E; Roschger P; Nell-Duxneuner V; Klaushofer K
Calcif Tissue Int; 2009 Mar; 84(3):159-70. PubMed ID: 19189037
[TBL] [Abstract][Full Text] [Related]
27. Mixed-treatment comparison of anabolic (teriparatide and PTH 1-84) therapies in women with severe osteoporosis.
Migliore A; Broccoli S; Massafra U; Bizzi E; Frediani B
Curr Med Res Opin; 2012 Mar; 28(3):467-73. PubMed ID: 22256908
[TBL] [Abstract][Full Text] [Related]
28. Osteoblasts in osteoporosis: past, emerging, and future anabolic targets.
Marie PJ; Kassem M
Eur J Endocrinol; 2011 Jul; 165(1):1-10. PubMed ID: 21543379
[TBL] [Abstract][Full Text] [Related]
29. Effect of osteoporosis medications on fracture healing.
Hegde V; Jo JE; Andreopoulou P; Lane JM
Osteoporos Int; 2016 Mar; 27(3):861-871. PubMed ID: 26419471
[TBL] [Abstract][Full Text] [Related]
30. Bone-forming agents in the management of osteoporosis.
Neuprez A; Reginster JY
Best Pract Res Clin Endocrinol Metab; 2008 Oct; 22(5):869-83. PubMed ID: 19028361
[TBL] [Abstract][Full Text] [Related]
31. The use of PTH in the treatment of osteoporosis.
Borba VZ; Mañas NC
Arq Bras Endocrinol Metabol; 2010 Mar; 54(2):213-9. PubMed ID: 20485911
[TBL] [Abstract][Full Text] [Related]
32. Parathyroid hormone as an anabolic skeletal therapy.
Rubin MR; Bilezikian JP
Drugs; 2005; 65(17):2481-98. PubMed ID: 16296873
[TBL] [Abstract][Full Text] [Related]
33. Anabolic effects of PTH and the 'anabolic window'.
Pazianas M
Trends Endocrinol Metab; 2015 Mar; 26(3):111-3. PubMed ID: 25662368
[TBL] [Abstract][Full Text] [Related]
34. Management of osteoporosis in rheumatoid arthritis patients.
Hoes JN; Bultink IE; Lems WF
Expert Opin Pharmacother; 2015 Mar; 16(4):559-71. PubMed ID: 25626121
[TBL] [Abstract][Full Text] [Related]
35. New therapeutic targets for osteoporosis.
Anagnostis P; Gkekas NK; Potoupnis M; Kenanidis E; Tsiridis E; Goulis DG
Maturitas; 2019 Feb; 120():1-6. PubMed ID: 30583758
[TBL] [Abstract][Full Text] [Related]
36. The role of parathyroid hormone in the management of osteoporosis.
Rosen CJ
Horm Res; 2005; 64 Suppl 2():81-5. PubMed ID: 16286779
[TBL] [Abstract][Full Text] [Related]
37. The future of osteoporosis treatment - a research update.
Lippuner K
Swiss Med Wkly; 2012; 142():w13624. PubMed ID: 22815185
[TBL] [Abstract][Full Text] [Related]
38. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal.
Cosman F; Nieves J; Woelfert L; Formica C; Gordon S; Shen V; Lindsay R
J Bone Miner Res; 2001 May; 16(5):925-31. PubMed ID: 11341338
[TBL] [Abstract][Full Text] [Related]
39. Management of postmenopausal osteoporosis and the prevention of fractures.
Gambacciani M; Levancini M
Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
[TBL] [Abstract][Full Text] [Related]
40. Abaloparatide: Recombinant human PTHrP (1-34) anabolic therapy for osteoporosis.
Chew CK; Clarke BL
Maturitas; 2017 Mar; 97():53-60. PubMed ID: 28159062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
